Background: Liraglutide is an incretin mimetic agent that approved recently in type-2 diabetes. The use of vitamin D is associated with an improvement of diabetic neuropathy. The aim of the study: Evaluation of the effect of liraglutide and vitamin D each alone and in combination with each other on diabetic neuropathy induced by streptozotocin in rats. Materials and Methods: Five groups of Wistar rats were used in the experiment. Diabetic neuropathy was induced in group 2, 3, 4 and 5 using single i.p. injection of streptozotocin in dose of 60 mg/kg. The third, fourth and fifth group were treated for 4 weeks with liraglutide (0.8 mg/kg), vitamin D3 (12 µg/kg) and combination of the 2 drugs, respectively. Then the behavioral tests were done (hot plate, tail flick, paw withdrawal pressure and the rotarod tests). Blood samples were used for assessment of blood glucose, TNF-α and IL-Iβ. Malondialdehyde and glutathione were measured in the sciatic nerve homogenate. Results: Liraglutide caused significant improvement of the behavioral tests of the diabetic rats with significant reduction in the blood glucose, TNF-α, IL-1β and malondialdehyde. Vitamin D caused mild improvement in the behavioral tests, inflammatory and oxidative stress markers. The combined use of liraglutide with vitamin D caused more improvement in diabetic neuropathy tests, inflammatory and oxidative stress markers. Conclusion: Liraglutide has a moderate neuroprotective, anti-inflammatory and antioxidant effects in cases of streptozotocin-induced diabetic neuropathy which are enhanced by the addition of vitamin